Figure 3.
Figure 3. Inhibition of anti–PF4/polysaccharide reactivity by fondaparinux. (Top) Solid-phase anti–PF4/UFH EIA. Mean (± SEM) reactivity of 5 HIT sera is shown in the absence (buffer) and presence of increasing concentrations of fondaparinux (100, 200, 400, or 1000 μg/mL, final). Progressive inhibition of reactivity is seen that is significant at all concentrations of fondaparinux. As expected, high heparin (100 IU/mL) also inhibited reactivity. (Bottom) Fluid-phase anti–PF4/UFH (•) and anti–PF4/LMWH (○) EIAs. Mean (± SEM) reactivity of 5 HIT sera is shown in the absence (buffer) and presence of increasing concentrations of fondaparinux (100, 200, 400, or 1000 μg/mL, final). Progressive inhibition of reactivity is seen that is significant at all concentrations of fondaparinux. High heparin (100 IU/mL) and enoxaparin (100 IU/mL) concentrations also inhibited reactivity.

Inhibition of anti–PF4/polysaccharide reactivity by fondaparinux. (Top) Solid-phase anti–PF4/UFH EIA. Mean (± SEM) reactivity of 5 HIT sera is shown in the absence (buffer) and presence of increasing concentrations of fondaparinux (100, 200, 400, or 1000 μg/mL, final). Progressive inhibition of reactivity is seen that is significant at all concentrations of fondaparinux. As expected, high heparin (100 IU/mL) also inhibited reactivity. (Bottom) Fluid-phase anti–PF4/UFH (•) and anti–PF4/LMWH (○) EIAs. Mean (± SEM) reactivity of 5 HIT sera is shown in the absence (buffer) and presence of increasing concentrations of fondaparinux (100, 200, 400, or 1000 μg/mL, final). Progressive inhibition of reactivity is seen that is significant at all concentrations of fondaparinux. High heparin (100 IU/mL) and enoxaparin (100 IU/mL) concentrations also inhibited reactivity.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal